Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07609719 · ClinicalTrials.gov registry record · Phase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
A Phase 4 study, sponsored by Genentech.
- Not yet
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT07609719 is a Phase 4 study that has not yet begun recruiting, run by Genentech. The registered enrollment target is 100 participants.
The verdict
NCT07609719, a Phase 4 study, has not yet begun recruiting, sponsored by Genentech.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV).
Interventions
- DRUG OCR SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-08-17 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07609719
The ClinicalTrials.gov registry entry for NCT07609719 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OCR SC is the first listed.
NCT07609719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07609719 about?
NCT07609719 is a clinical study titled "A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy". The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or p...
What is the current status of trial NCT07609719?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-08-17. Estimated completion is 2029-02-28.
What interventions are being tested in trial NCT07609719?
The interventions under investigation include: OCR SC (DRUG).
Who is sponsoring clinical trial NCT07609719?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.